SHE: 300601

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already…

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

CompanyDeals

Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines

Show More